tiprankstipranks
Sangamo Therapeutics (SGMOQ)
OTHER OTC:SGMOQ
US Market
SGMOQ
Sangamo Therapeutics
RESEARCH TOOLSreports
Want to see SGMOQ full AI Analyst Report?

Sangamo Therapeutics (SGMOQ) Stock Forecast & Price Target

2,692 Followers
See the Price Targets and Ratings of:

SGMOQ Analyst Ratings

Hold
1Ratings
Hold
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Sangamo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SGMOQ Stock 12 Month Forecast

Average Price Target

$2.00
▲(3233.33% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 3233.33% change from the last price of $0.06.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.073,0.22123076923076923,0.36946153846153845,0.5176923076923077,0.6659230769230768,0.814153846153846,0.9623846153846153,1.1106153846153846,1.2588461538461537,1.407076923076923,1.555307692307692,1.7035384615384614,1.8517692307692306,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.073,0.22123076923076923,0.36946153846153845,0.5176923076923077,0.6659230769230768,0.814153846153846,0.9623846153846153,1.1106153846153846,1.2588461538461537,1.407076923076923,1.555307692307692,1.7035384615384614,1.8517692307692306,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.073,0.22123076923076923,0.36946153846153845,0.5176923076923077,0.6659230769230768,0.814153846153846,0.9623846153846153,1.1106153846153846,1.2588461538461537,1.407076923076923,1.555307692307692,1.7035384615384614,1.8517692307692306,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.561,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.539,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.674,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.598,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.425,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.567,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.429,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.211,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.057,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.073,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2.00Average Price Target$2.00Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on SGMOQ
Luca Issi
RBC Capital
RBC Capital
$2
Hold
3233.33%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Sangamo Therapeutics (Other OTC: SGMO) and Insight Molecular Diagnostics (NASDAQ: IMDX)
Wells Fargo Analyst forecast on SGMOQ
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$4→$2
Hold
3233.33%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on SGMOQ
Gena Wang
Barclays
Barclays
$5→$1
Hold
1566.67%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on SGMOQ
Luca Issi
RBC Capital
RBC Capital
$2
Hold
3233.33%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Sangamo Therapeutics (Other OTC: SGMO) and Insight Molecular Diagnostics (NASDAQ: IMDX)
Wells Fargo Analyst forecast on SGMOQ
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$4→$2
Hold
3233.33%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on SGMOQ
Gena Wang
Barclays
Barclays
$5→$1
Hold
1566.67%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sangamo Therapeutics

3 Months
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
1/4 ratings generated profit
25%
Average Return
-31.52%
Copying PerPlexity Biotechnology's trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -31.52% per trade.
1 Year
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
1/4 ratings generated profit
25%
Average Return
-31.52%
Copying PerPlexity Biotechnology's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -31.52% per trade.
2 Years
PerPlexity BiotechnologyTipRanks - PerPlexity
Success Rate
1/4 ratings generated profit
25%
Average Return
-31.52%
Copying PerPlexity Biotechnology's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -31.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGMOQ Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
4
4
3
1
0
Buy
0
0
0
0
0
Hold
1
2
3
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
6
4
2
In the current month, SGMOQ has received 0 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. SGMOQ average Analyst price target in the past 3 months is 2.00.
Each month's total comprises the sum of three months' worth of ratings.

SGMOQ Financial Forecast

SGMOQ Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

SGMOQ Sales Forecast

The previous quarter’s earnings for SGMOQ were $108.95K.
The previous quarter’s earnings for SGMOQ were $108.95K.

SGMOQ Stock Forecast FAQ

What is SGMOQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Sangamo Therapeutics’s 12-month average price target is 2.00.
    What is SGMOQ’s upside potential, based on the analysts’ average price target?
    Sangamo Therapeutics has 3233.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SGMOQ a Buy, Sell or Hold?
          Sangamo Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Sangamo Therapeutics’s price target?
            The average price target for Sangamo Therapeutics is 2.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $2.00 ,the lowest forecast is $2.00. The average price target represents 3233.33% Increase from the current price of <$0.1.
              What do analysts say about Sangamo Therapeutics?
              Sangamo Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of SGMOQ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.